体内分布
肾
肾功能
医学
药理学
肾缺血
缺血
体内
再灌注损伤
病理
内科学
生物
生物技术
作者
Mikhail Burmakin,Peter S. Gilmour,Magnus Gram,Nelli Shushakova,Ruben M. Sandoval,Bruce A. Molitoris,Tobias E. Larsson
出处
期刊:American Journal of Physiology-renal Physiology
[American Physical Society]
日期:2024-05-23
卷期号:327 (1): F103-F112
被引量:1
标识
DOI:10.1152/ajprenal.00067.2024
摘要
A therapeutic A1M protein variant (RMC-035) is currently in phase 2 clinical development for renal protection in patients undergoing open-chest cardiac surgery. It targets several key pathways underlying kidney injury in this patient group, including oxidative stress, heme toxicity, and mitochondrial dysfunction. RMC-035 is rapidly eliminated from plasma, distributing to kidney proximal tubules, and demonstrates dose-dependent efficacy in numerous models of ischemia-reperfusion injury, particularly when administered before ischemia. These results support its continued clinical evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI